Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Tofacitinib-XELJANZ: Potential New Treatment Option For Moderate To Severe Ulcerative Colitis
MedicalResearch.
Trump scores healthcare victory in House
The US House of Representatives has passed a healthcare bill, bringing President Trump's pledge to repeal and replace Obamacare a stride closer.
Vertex veers upwards on reporting rising profits and sales
A 22% increase in its net revenue was reported by US biotech Vertex Pharmaceuticals (Nasdaq.
FDA Approves Xatmep
Denver, April 26, 2017 — Silvergate Pharmaceuticals, Inc.
CFDA approved HCV treatment by Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that the China Food and Drug Administration (CFDA) has approved a direct-acting antiviral regimen comprised of Daklinza (daclatasvir) and Sunvepr...
Ocrevus is Here: Thoughts and Perspectives from DRG
In early April 2017, Roche/Genentech launched its hotly-anticipated anti-CD20 monoclonal antibody Ocrevus (ocrelizumab) for the treatment of relapsing forms of MS (RMS) and—in a land...
FDA Approves Alunbrig (brigatinib) for Rare Lung Cancer
On Friday evening, Takeda Pharmaceuticals announced the FDA has approved Alunbrig (brigatinib) to treat patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-smal...
AstraZeneca immunotherapy wins first approval in bladder cancer
U.
Chemotherapy drug shows promise in relapsing MS
German pharma major Merck KGaA (MRK.
FDA Approves Tymlos (abaloparatide) for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
WALTHAM, Mass.
FDA Approves BioMarin's Batten Disease Drug. Cost Per Year is $702,000
Following the FDA approval of Brineura (cerliponase alfa), BioMarin announced the enzyme replacement therapy will cost $27,000 per biweekly infusion.
Beta blocker shows cancer-fighting properties
A new study finds that carvedilol, a drug typically used to treat high blood pressure, can protect against the sun-induced cell damage that leads to skin cancer.
516
517
518
519
520
521
522
523
524
